
1698: Oxymoronic
23andMe Board Resignations and Potential Privatization
The entire board of directors at 23andMe has resigned following a disagreement with CEO Anne Wojcicki over her proposal to take the company private. The genetic testing firm faces a potential Nasdaq delisting as its stock price has fallen below one dollar. Concerns are raised regarding the security of consumer DNA data as the company struggles with financial instability and a lack of independent oversight.





